Cathflo Activase (alteplase) 2 mg is the standard of care for treatment of thrombotically occluded catheters
Cathflo is the only thrombolytic agent1-8:
- FDA approved for the restoration of function to central venous access devices as assessed by the ability to withdraw blood1
- Recommended by clinical practice standards, including the Infusion Nursing Society (INS), Association for Vascular Access (AVA), and the Oncology Nurses Society (ONS)2-7
- Available in a single-use, 2-mg vial8
- With an efficacy and safety profile demonstrated in adult and pediatric patients
Cathflo® Activase® (alteplase) is indicated for the restoration of function to central venous access devices as assessed by the ability to withdraw blood.
Important Safety Information
Cathflo Activase should not be administered to patients with known hypersensitivity to alteplase or any component of the formulation.
Certain causes of catheter dysfunction should be considered before treatment with Cathflo Activase (e.g. catheter malposition, mechanical failure, constriction by a suture and lipid deposits or drug precipitates within the catheter lumen).
Excessive pressure should be avoided when Cathflo Activase is instilled into the catheter.
The most frequent adverse reaction associated with all thrombolytics in all approved indications is bleeding. Cathflo Activase has not been studied in patients known to be at risk for bleeding events that may be associated with the use of thrombolytics. Caution should be exercised with patients who have any condition for which bleeding constitutes a significant hazard.
Should serious bleeding in a critical location (e.g., intracranial, gastrointestinal, retroperitoneal, pericardial) occur, treatment with Cathflo Activase should be stopped and the drug should be withdrawn from the catheter.
Cathflo Activase should be used with caution in the presence of known or suspected infection in the catheter. Using Cathflo Activase in patients with infected catheters may release a localized infection into the systemic circulation.
In clinical trials, the most serious adverse events reported after treatment were sepsis, gastrointestinal bleeding, and venous thrombosis.
Please see full Prescribing Information for additional Important Safety Information.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech.
Genentech makes no representation as to the accuracy of the information contained on sites we do not own or control.
Genentech does not recommend and does not endorse the content on any third-party websites.
Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
Return to Site
The information contained in this site is intended for US residents only.
© 2017 Genentech USA, Inc. All rights reserved.
1 DNA Way
South San Francisco, CA 94080-4990